RA Capital Management, a private equity firm, led a $175m Series B round in Capstan Therapeutics, a biotechnology company, with participation from Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures. “We are proud to support Capstan and their mission to lead in vivo CAR-T. Our conviction in Capstan is a result of the confluence of a differentiated platform technology that enables efficient T cell engineering, the platform’s ideal application in a large autoimmune market being disrupted by ex vivo CAR-T therapy, and a seasoned management team that is working tirelessly to advance this technology into patients," Nandita Shangari, RA Capital Management Managing Director.